Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced completion of its previously planned clinical studies for the Symphony IL-6 Test (the “Test”). Results of these studies will be published at the 2022 AACC Annual Scientific Meeting being held July 26th to 28th in Chicago.
